Extracorporeal photopheresis: Lighting the way to immunomodulation

American Journal of Hematology

Volumn 83, Issue 7, 2008, Pages 589-591

  Babic, Aleksandar M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; METHOXSALEN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CARDIAC GRAFT REJECTION; CD4+ CD25+ T LYMPHOCYTE; CELL MATURATION; CELLULAR IMMUNITY; CHRONIC GRAFT VERSUS HOST DISEASE; CUTANEOUS T CELL LYMPHOMA; EXTRACORPOREAL PHOTOPHERESIS; GRAFT RECIPIENT; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PUVA; REGULATORY T LYMPHOCYTE; TREATMENT INDICATION; ULTRAVIOLET A RADIATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; CHRONIC DISEASE; GRAFT VS HOST DISEASE; HUMANS; IMMUNE TOLERANCE; LYMPHOMA, T-CELL, CUTANEOUS; ORGAN TRANSPLANTATION; PHOTOPHERESIS;

EID: 45749136885     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21166     Document Type: Article

References (51)

1. Maeda A, Schwarz A, Kernebeck K, et al. Intravenous infusion of syngeneic apoptotic cells by photopheresis induces antigen-specific regulatory T cells. J Immunol 2005;174:5968-5976.
2. Peritt D. Potential mechanisms of photopheresis in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006;12:7-12.
3. Foss FM. New insights into the mechanism of action of extracorporeal phototherapy. Transfusion 2006;46:6-9.
4. Edelson R, Berger C, Gasparro F, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med 1987;316:297-303.
5. Marques MB, Tuncer HH. Photopheresis in solid organ transplant rejection. J Clin Apher 2006;21:72-77.
6. Rook AH, Cohen JH, Lessin SR, et al. Therapeutic applications of photopheresis. Dermatol Clin 1993;11:339-347.
7. Lebwohl M, Martinez J, Weber P, et al. Effects of topical preparations on the erythemogenicity of UVB: Implications for psoriasis phototherapy. J Am Acad Dermatol 1995;32:469-471.
8. Reynolds NJ, Franklin V, Gray JC, et al. Narrow-band ultraviolet B and broadband ultraviolet A phototherapy in adult atopic eczema: A randomised controlled trial. Lancet 2001;357:2012-2016.
9. Lynch WS, Roenigk HH Jr. Essentials for PUVA therapy. Guidelines for photochemotherapy. Cutis 1977;20:494-501.
10. Gilchrest BA. Methoxsalen photochemotherapy for mycosis fungoides. Cancer Treat Rep 1979;63:663-667.
11. Heald P, Rook A, Perez M, et al. Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J Am Acad Dermatol 1992;27:427-433.
12. Lim HW, Edelson RL. Photopheresis for the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995;9:1117-1126.
13. Suchin KR, Cassin M, Washko R, et al. Extracorporeal photochemotherapy does not suppress T- or B-cell responses to novel or recall antigens. J Am Acad Dermatol 1999;41:980-986.
14. Duvic M. Response rates in photopheresis therapy for cutaneous T cell lymphoma. J Am Acad Dermatol 1997;37:288.
15. Jackow CM, Cather JC, Hearne V, et al. Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V β gene expansion. Blood 1997;89:32-40.
16. Edelson RL. Cutaneous T cell lymphoma: The helping hand of dendritic cells. Ann N Y Acad Sci 2001;941:1-11.
17. Berger CL, Hanlon D, Kanada D, et al. Transimmunization, a novel approach for tumor immunotherapy. Transfus Apher Sci 2002;26:205-216.
18. Gasparro FP, Dall'Amico R, Goldminz D, et al. Molecular aspects of extracorporeal photochemotherapy. Yale J Biol Med 1989;62:579-593.
19. Yoo EK, Rook AH, Elenitsas R, et al. Apoptosis induction of ultraviolet light A and photochemotherapy in cutaneous T-cell Lymphoma: Relevance to mechanism of therapeutic action. J Invest Dermatol 1996;107:235-242.
20. Berger CL, Xu AL, Hanlon D, et al. Induction of human tumor-loaded dendritic cells. Int J Cancer 2001;91:438-447.
21. Girardi M, Berger CL, Wilson LD, et al. Transimmunization for cutaneous T cell lymphoma: A phase I study. Leuk Lymphoma 2006;47:1495-1503.
22. Higman MA, Vogelsang GB. Chronic graft versus host disease. Br J Haematol 2004;125:435-454.
23. Reddy P. Pathophysiology of acute graft-versus-host disease. Hematol Oncol 2003;21:149-161.
24. Zhang C, Todorov I, Zhang Z, et al. Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood 2006;107:2993-3001.
25. Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151-1164.
26. Zorn E, Kim HT, Lee SJ, et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood 2005;106:2903-2911.
27. Mork NJ, Gaudernack G, Braathen LR. Effect of UVA and PUVA on alloactivating and antigen-presenting capacity of human epidermal Langerhans cells. Photodermatol 1987;4:66-72.
28. Apisarnthanarax N, Donato M, Korbling M, et al. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: Feasibility and results. Bone Marrow Transplant 2003;31:459-465.
29. Foss FM, DiVenuti GM, Chin K, et al. Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: Analysis of response and survival incorporating prognostic factors. Bone Marrow Transplant 2005;35:1187-1193.
30. Greinix HT, Volc-Platzer B, Rabitsch W, et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 1998;92:3098-3104.
31. Seaton ED, Szydlo RM, Kanfer E, et al. Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of response. Blood 2003;102:1217-1223.
32. Baadsgaard O. In vivo ultraviolet irradiation of human skin results in profound perturbation of the immune system. Relevance to ultraviolet-induced skin cancer. Arch Dermatol 1991;127:99-109.
33. Norval M, Garssen J, Van Loveren H, et al. UV-induced changes in the immune response to microbial infections in human subjects and animal models. J Epidemiol 1999;9:S84-S92.
34. Spellman CW, Woodward JG, Daynes RA. Modification of immunological potential by ultraviolet radiation. I. Immune status of short-term UV-irradiated mice. Transplantation 1977;24:112-119.
35. Schwarz A, Maeda A, Wild MK, et al. Ultraviolet radiation-induced regulatory T cells not only inhibit the induction but can suppress the effector phase of contact hypersensitivity. J Immunol 2004;172:1036-1043.
36. Schwarz T. Ultraviolet radiation-induced tolerance. Allergy 1999;54:1252-1261.
37. Simon JC, Hara H, Denfeld RW, et al. UVB-irradiated dendritic cells induce nonproliferating, regulatory type T cells. Skin Pharmacol Appl Skin Physiol 2002;15:330-334.
38. Aubin F, Mousson C. Ultraviolet light-induced regulatory (suppressor) T cells: An approach for promoting induction of operational allograft tolerance? Transplantation 2004;77:S29-S31.
39. Gorgun G, Miller KB, Foss FM. Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease. Blood 2002;100:941-947.
40. Spisek R, Gasova Z, Bartunkova J. Maturation state of dendritic cells during the extracorporeal photopheresis and its relevance for the treatment of chronic graft-versus-host disease. Transfusion 2006;46:55-65.
41. Roncarolo MG, Gregori S, Battaglia M, et al. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev 2006;212:28-50.
42. Loser K, Apelt J, Voskort M, et al. IL-10 controls ultraviolet-induced carcinogenesis in mice. J Immunol 2007;179:365-371.
43. Pepino P, Berger CL, Fuzesi L. et al. Primate cardiac allo-and xenotransplantation: Modulation of the immune response with photochemotherapy. Eur Surg Res 1989;21:105-113.
44. Perez M, Edelson R, Laroche L, et al. Inhibition of antiskin allograft immunity by infusions with syngeneic photoinactivated effector lymphocytes. J Invest Dermatol 1989;92:669-676.
45. Meiser BM, Kur F, Reichenspurner H, et al. Reduction of the incidence of rejection by adjunct immunosuppression with photochemotherapy after heart transplantation. Transplantation 1994;57:563-568.
46. Rose EA, Barr ML, Xu H, et al. Photochemotherapy in human heart transplant recipients at high risk for fatal rejection. J Heart Lung Transplant 1992;11:746-750.
47. Barr ML, Meiser BM, Eisen HJ, et al. Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group. N Engl J Med 1998;339:1744-1751.
48. Astor TL, Weill D. Extracorporeal photopheresis in lung transplantation. J Cutan Med Surg 2003;7:20-24.
49. Slovis BS, Loyd JE, King LE Jr. Photopheresis for chronic rejection of lung allografts. N Engl J Med 1995;332:962.
50. Lamioni A, Parisi F, Isacchi G, et al. The immunological effects of extracorporeal photopheresis unraveled: Induction of tolerogenic dendritic cells in vitro and regulatory T cells in vivo. Transplantation 2005;79:846-850.
51. Biagi E, Di Biaso I, Leoni V, et al. Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+ Foxp3+CD62L+ functional regulatory T-cells in patients with graft-versus-host disease. Transplantation 2007;84:31-39.